DCM
GENE

Davis Capital Management’s Genetic Technologies Ltd. GENE Stock Holding History

Davis Capital Management’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$2K Hold
200
– – ﹤0.01% 252
2020
Q1 		$2K Buy
+200
New +$3.18K ﹤0.01% 244

Other funds holding GENE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Davis Capital Management's GENE Position: Q2 2020 in Review

Davis Capital Management held its Genetic Technologies Ltd. (GENE) position steady in Q2 2020 at 200 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #252.

Davis Capital Management first reported a position in GENE in Q1 2020 and has held it in 2 quarters since. 10 funds tracked by Wall St. Rank hold GENE as of Q2 2020.

  • Davis Capital Management held 200 shares of Genetic Technologies Ltd. worth $2K as of Q2 2020.
  • Davis Capital Management left its Genetic Technologies Ltd. share count unchanged in Q2 2020.
  • Genetic Technologies Ltd. made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2020, its #252 holding.
  • Davis Capital Management first reported a position in Genetic Technologies Ltd. in Q1 2020 and has held it in 2 quarters since.
  • 10 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q2 2020.

Based on Davis Capital Management's 13F filing for Q2 2020, filed 29 Jul 2020.